Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 67

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 1
Chunk 67
---
 to achieve and maintain sufficient commercial market acceptance of our existing and future products will depend on a number of factors, including: 

•our ability to increase awareness of our Genomics and AI Applications diagnostic tests and other AI Applications, including new product offerings as they become available; 

•the rate of adoption and/or endorsement of our Genomics and AI Applications diagnostic tests and AI Applications by clinicians, pharmaceutical and biotechnology companies, KOLs, and advocacy groups; 

•the timing and scope of obtaining any necessary approvals or certification by regulatory authorities, including the FDA, for our diagnostic tests, any software offerings, AI Applications, or any features of our Platform, in each case, that may be subject to regulatory oversight; 

•our ability to obtain positive coverage decisions for our tests from additional commercial payers and to broaden the scope of indications included in such coverage decisions; 

•our ability to obtain reimbursement and expanded coverage from government payers, including Medicare or comparable foreign programs; 

53

•our ability to increase demand for our Data business, including by expanding our database of de- identified patient information and increasing the utility of our product offerings; 

•our ability to successfully expand beyond oncology into neuropsychiatry, cardiology, radiology, and other indications; 

•our ability to build and maintain robust data sets with respect to patient populations in geographic regions that we may seek to enter in the future; 

•the impact of our investments in Platform development, product innovation and commercial growth; 

•public perception of our products, those of our competitors and the industry in which we operate, including our ability to avoid adverse publicity from defects or errors; and 

•our ability to further validate our Platform through clinical research and accompanying publications. 

We cannot assure that we will be successful in addressing each of these criteria or other criteria that might affect the market acceptance of our products. If we are unsuccessful in achieving and maintaining sufficient market acceptance of our products, our business, financial condition and results of operations will suffer. 

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. 

Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. Because we plan to operate our business with a long-term focus, these fluctuations may be more pronounced than those experienced by other companies that operate with a shorter- term focus. These fluctuations may occur due to a variety of factors, many